ENTA logo

ENTA
Enanta Pharmaceuticals Inc

1,155
Mkt Cap
$403.08M
Volume
161,447.00
52W High
$17.15
52W Low
$4.96
PE Ratio
-4.48
ENTA Fundamentals
Price
$14.35
Prev Close
$13.89
Open
$13.89
50D MA
$13.57
Beta
1.10
Avg. Volume
118,774.85
EPS (Annual)
-$3.84
P/B
3.29
Rev/Employee
$544,366.67
$267.58
Loading...
Loading...
News
all
press releases
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Recommendation of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven ha...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Above 50-Day Moving Average - Here's Why
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Above 50 Day Moving Average - Should You Sell...
MarketBeat·16d ago
News Placeholder
Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that the...
Business Wire·19d ago
News Placeholder
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that data...
Business Wire·25d ago
News Placeholder
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of "Moderate Buy" by Brokerages
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat Ratings reports...
MarketBeat·29d ago
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Shares Pass Below 200 Day Moving Average - Should You Sell?
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Price Crosses Below Two Hundred Day Moving Average - Here's Why...
MarketBeat·29d ago
News Placeholder
Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that...
Business Wire·1mo ago
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Now Covered by Analysts at Rodman & Renshaw
Rodman & Renshaw started coverage on Enanta Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $20.00 target price for the company...
MarketBeat·1mo ago
News Placeholder
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below Two Hundred Day Moving Average - What's Next?
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Passes Below 200 Day Moving Average - Time to Sell...
MarketBeat·1mo ago
News Placeholder
Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens Conference
Enanta Pharmaceuticals (NASDAQ:ENTA) used a presentation at the Citizens Life Sciences Conference to outline its evolving pipeline strategy, highlighting late-stage ambitions in respiratory syncytial...
MarketBeat·2mo ago
<
1
2
...
>

Latest ENTA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.